Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone Acetate Without Prednisone in CRPC
NCT02025010Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2014
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abiraterone in castration-resistant prostate cancer (CRPC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Number of Participants With Toxicities That Required the Addition of Prednisone to Manage Symptoms of Persistent or Severe Mineralocorticoid Excess up to 57 months. Started Jan 2014; status: completed.
02
Drugs
abiraterone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02025010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02025010.